The Journey to Better Care: Diagnostics Beyond COVID-19
The COVID-19 pandemic has highlighted the importance of early detection and prevention in ensuring national health and wellbeing. As more people recognise the critical role diagnostics has played, how can this understanding similarly translate to screening and diagnosis beyond the COVID-19 pandemic?
Proactive and preventative care also has knock on effects in terms of productivity and economic benefits. The adoption of a sustainable health delivery model requires a change in thinking and behaviour across all stakeholder groups – the informed public, clinicians, payers, and policy makers.
A global survey conducted by Roche Diagnostics uncovers the attitudes and understanding of key stakeholders around the impact of diagnostics on health systems today. In the 4th edition of Dia:gram Media Forum we explore these findings as well as the challenges and opportunities of what diagnostics looks like in the New Normal, beyond COVID-19.
Diagnostics Beyond COVID-19
Throughout history, diagnostics have played an essential role in every step of the patient journey, from detecting potential health issues earlier to determining appropriate treatments right down to monitoring treatment efficacy. How has COVID-19 changed these perceptions? This panel discussion will focus on how current and new diagnostic tools will continue to transform healthcare systems for better outcomes – for patients and societies at large.
Dr Bushra Jamil
Professor of Medicine and Infectious Diseases, Aga Khan University Hospital and President, Medical Microbiology & Infectious Diseases Society of Pakistan (MMIDSP)
Dr. Bushra Jamil is a Professor at the Section of Infectious Diseases, The Aga Khan University, where her research specialises in sepsis, disease outbreaks, infection prevention and control, as well as antimicrobial resistance. She is one of the very first practicing Infectious Diseases Physician in Pakistan.
Director, The Voices Project
(A Sovereign Health Initiative)
With over 20 years of active healthcare experience across multiple emerging and developed markets, Rohit Sahgal brings a well-attuned and unique commercial perspective to help navigate through the complexities of the policy and health education ecosystem. Rohit has developed an approach to healthcare communications that is rooted in understanding the nuances of engaging with audiences from across multilateral, government affairs and regulatory roles. He currently is Technical Advisor to WHO’s Western Pacific Region for NCD and Cervical Cancer Prevention & Control.
Prof Yang Pei-Ming
Professor Emeritus of Medicine, National Taiwan University College of Medicine and Chief Executive Officer, Liver Disease Prevention & Treatment Research Foundation
Prof Yang Pei-Ming is a Professor Emeritus of Medicine at the National Taiwan University College of Medicine, specialising in abdominal ultrasound, gastroenterology and hepatology, internal medicine and medical education. Prof Yang current presides the Taiwan Society of Internal Medicine and previously the Taiwan Society of Ultrasound in Medicine.
Value of Diagnostics
In 2021, Roche Diagnostics compiled research data from the public, healthcare providers and policymakers, across 11 countries globally, including two countries in Asia Pacific, on their perspectives of the impact of diagnostics in healthcare systems today. This panel discussion will dive deeper into the results of this research on the attitudes and knowledge of diagnostics across the region. Most importantly, the panel will discuss why recognising the value of diagnostics and further integrating diagnostics into health systems is critical to improving health outcomes.
Managing Director, Region Asia Pacific, Roche Diagnostics
Lance Little became the Managing Director, Region Asia Pacific for Roche Diagnostics in 2012. Prior to that, he was the Managing Director of Roche Diagnostics India, where he was also the head of the wider Indian sub-region. Prior to this, his experience as Managing Director extended to both Roche Diagnostics Thailand and Roche Diagnostics New Zealand.
Dr Rengaswamy Sankaranarayanan
Director, Preventive Oncology, Karkinos Healthcare, India and Senior Visiting Scientist, International Agency for Research on Cancer (WHO-IARC)
Dr Rengaswamy Sankaranarayanan has conducted several studies in multinational, multicultural and varying resourced environments, with the aim of providing scientific evidence to support the development of appropriate public health policies for the screening and early diagnosis of common cancers. Dr Sankaranarayanan advises several governments on cancer early detection and control and has been consistently ranked among the top 1% of medical researchers globally.